← ANALYST RATINGS · TIPRANKS
Krystal Biotech (KRYS): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy1 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $404, the highest $441, the lowest $361. The average is +27.5% from the last price of $317.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $414 → $374−9.7% | Buy | +18.1% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $406 → $370−8.9% | Buy | +16.9% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $405 → $375−7.4% | Buy | +18.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $392 → $380−3.1% | Buy | +20.0% | Upgrade | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $410 → $379−7.6% | Buy | +19.7% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $424 → $372−12.3% | Buy | +17.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $386 → $416+7.8% | Buy | +31.4% | Reiterated | 15.10.26on TipRanks 13:20 | −0.5%next day −3.0% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $361 | Buy | +14.0% | Reiterated | 15.10.26on TipRanks 12:35 | −0.5%next day −3.0% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $400 | Buy | +26.4% | Reiterated | 08.10.26on TipRanks 21:45 | +0.7%next day +0.2% · 5 days −2.6% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $441 | Buy | +39.3% | Initiated | 24.09.26on TipRanks 04:35 | +1.0%next day −0.3% · 5 days −5.3% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $392 → $400+2.0% | Buy | +26.4% | Reiterated | 21.09.26on TipRanks 06:45 | −2.4%next day +5.1% · 5 days +2.0% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | — | Hold | — | Reiterated | 11.08.26on TipRanks Aug 12 10:15 | −1.0%next day +1.5% · 5 days +2.2% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $403 | Buy | +27.3% | Reiterated | 03.08.26on TipRanks Aug 4 01:20 | −9.8%next day +2.1% · 5 days +4.1% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 03.08.26on TipRanks 11:55 | −9.8%next day +2.1% · 5 days +4.1% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $474 | Buy | +49.7% | Assigned | 13.07.26on TipRanks 08:50 | +0.1%next day −7.0% · 5 days −5.7% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $295 → $300+1.7% | Buy | −5.2% | Reiterated | 05.05.26on TipRanks 08:20 | −1.6%next day +0.2% · 5 days +7.1% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $284 | Buy | −10.3% | Reiterated | 04.05.26on TipRanks May 5 07:15 | +8.2%next day −1.6% · 5 days +6.1% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $323 | Buy | +2.0% | Reiterated | 04.05.26on TipRanks 14:05 | +8.2%next day −1.6% · 5 days +6.1% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $338 → $311−8.0% | Buy | −1.8% | Reiterated | 04.05.26on TipRanks 12:07 | +8.2%next day −1.6% · 5 days +6.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Krystal Biotech
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $409 at a price of $333 (+23.1%); now: $404 at $317 (+27.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 17 | 19 | 20 | 12 | 11 | 11 |
| Hold | 1 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.83 (from $1.60 to $2.15). Last quarter: $1.79.
Sales
Next quarter’s sales estimate — $127M (from $123M to $134M). Last quarter: $119M.
Best top-analyst consensus in the sector · Healthcare
About Krystal Biotech
- CEO: Krish S. Krishnan
- Employees: 295
- 2100 Wharton Street, Pittsburgh, PA, 15203, US
- www.krystalbio.com
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 88 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗